Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

IntroductionPD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management.MethodsWe analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012 to 2020 in a German academic center.ResultsIrAE s...

Full description

Bibliographic Details
Main Authors: Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, Hannah Schindler, Rajiv Shah, Anna-Lena Volckmar, Fabienne Lusky, Leonore Diekmann, Stephan Liersch, Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
immune-related adverse events
immunotherapy
immune-checkpoint inhibitors
treatment interruption
prognosis
lethality
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.703893/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.703893/full

Similar Items